Cybin Continues To Expect To Commence Phase 3 Pivotal Program In Late Summer; It Had Type B Initial Breakthrough Therapy Meeting With FDA Late Last Week

Author: Benzinga Newsdesk | August 13, 2024 07:37am

Doug Drysdale, Chief Executive Officer of Cybin, said, "Having selected 30 clinical sites across the United States and Europe, we are eager to initiate this next phase of clinical development and to build on the positive impact of CYB003 to date. In our Phase 2 study, CYB003 showed a robust and sustained effect, with 75% of patients in remission from depression four months after two 16mg doses. We expect to report 12-month efficacy data from the Phase 2 study in the fourth quarter of this year."

Posted In: CYBN